Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
2
7
2020
medline:
8
10
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment, is desirable for patients. This study aims to develop a population PK (PopPK) model to characterize and predict the PK profiles of mitotane in patients with ACC, as well as to explore the effect of genetic variation on mitotane clearance. Ultimately, we aimed to facilitate mitotane dose optimization and individualization for patients with ACC. Mitotane concentration and dosing data were collected retrospectively from the medical records of patients with ACC taking mitotane orally and participating in the Dutch Adrenal Network. PopPK modelling analysis was performed using NONMEM (version 7.4.1). Genotypes of drug enzymes and transporters, patient demographic information, and clinical characteristics were investigated as covariates. Subsequently, simulations were performed for optimizing treatment regimens. A two-compartment model with first-order absorption and elimination best described the PK data of mitotane collected from 48 patients. Lean body weight (LBW) and genotypes of CYP2C19*2 (rs4244285), SLCO1B3 699A>G (rs7311358) and SLCO1B1 571T>C (rs4149057) were found to significantly affect mitotane clearance (CL/F), which decreased the coefficient of variation (CV%) of the random inter-individual variability of CL/F from 67.0 to 43.0%. Fat amount (i.e. body weight - LBW) was found to significantly affect the central distribution volume. Simulation results indicated that determining the starting dose using the developed model is beneficial in terms of shortening the period to reach the therapeutic target and limit the risk of toxicity. A regimen that can effectively maintain mitotane concentration within 14-20 mg/L was established. A two-compartment PopPK model well-characterized mitotane PK profiles in patients with ACC. The CYP2C19 enzyme and SLCO1B1 and SLCO1B3 transporters may play roles in mitotane disposition. The developed model is beneficial in terms of optimizing mitotane treatment schedules and individualizing the initial dose for patients with ACC. Further validation of these findings is still required.
Sections du résumé
BACKGROUND
Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment, is desirable for patients.
OBJECTIVES
This study aims to develop a population PK (PopPK) model to characterize and predict the PK profiles of mitotane in patients with ACC, as well as to explore the effect of genetic variation on mitotane clearance. Ultimately, we aimed to facilitate mitotane dose optimization and individualization for patients with ACC.
METHODS
Mitotane concentration and dosing data were collected retrospectively from the medical records of patients with ACC taking mitotane orally and participating in the Dutch Adrenal Network. PopPK modelling analysis was performed using NONMEM (version 7.4.1). Genotypes of drug enzymes and transporters, patient demographic information, and clinical characteristics were investigated as covariates. Subsequently, simulations were performed for optimizing treatment regimens.
RESULTS
A two-compartment model with first-order absorption and elimination best described the PK data of mitotane collected from 48 patients. Lean body weight (LBW) and genotypes of CYP2C19*2 (rs4244285), SLCO1B3 699A>G (rs7311358) and SLCO1B1 571T>C (rs4149057) were found to significantly affect mitotane clearance (CL/F), which decreased the coefficient of variation (CV%) of the random inter-individual variability of CL/F from 67.0 to 43.0%. Fat amount (i.e. body weight - LBW) was found to significantly affect the central distribution volume. Simulation results indicated that determining the starting dose using the developed model is beneficial in terms of shortening the period to reach the therapeutic target and limit the risk of toxicity. A regimen that can effectively maintain mitotane concentration within 14-20 mg/L was established.
CONCLUSIONS
A two-compartment PopPK model well-characterized mitotane PK profiles in patients with ACC. The CYP2C19 enzyme and SLCO1B1 and SLCO1B3 transporters may play roles in mitotane disposition. The developed model is beneficial in terms of optimizing mitotane treatment schedules and individualizing the initial dose for patients with ACC. Further validation of these findings is still required.
Identifiants
pubmed: 32607875
doi: 10.1007/s40262-020-00913-y
pii: 10.1007/s40262-020-00913-y
pmc: PMC7809008
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Liver-Specific Organic Anion Transporter 1
0
SLCO1B1 protein, human
0
Mitotane
78E4J5IB5J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-102Références
CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):3-10
pubmed: 26844010
Curr Opin Mol Ther. 2009 Jun;11(3):260-8
pubmed: 19479659
Oncologist. 2016 Feb;21(2):220-32
pubmed: 26668254
Pharmaceutics. 2019 Oct 31;11(11):
pubmed: 31683663
Clin Endocrinol (Oxf). 2010 Aug;73(2):271-2
pubmed: 20105188
Pharmacogenomics. 2010 Jan;11(1):89-103
pubmed: 20017675
Eur Endocrinol. 2018 Sep;14(2):62-66
pubmed: 30349596
Pharmacol Res Perspect. 2015 Mar;3(2):e00131
pubmed: 26038706
Blood. 2008 Apr 15;111(8):4106-12
pubmed: 18250228
Cancer Chemother Pharmacol. 1981;7(1):51-4
pubmed: 7340988
J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67
pubmed: 24057287
Pharm Res. 1998 Sep;15(9):1463-8
pubmed: 9755901
Cancer Chemother Pharmacol. 1982;9(2):85-8
pubmed: 7172409
Oncotarget. 2016 Aug 16;7(33):54028-54050
pubmed: 27304055
Lancet Oncol. 2005 Oct;6(10):780-9
pubmed: 16198984
Pharmacogenet Genomics. 2013 Jun;23(6):293-300
pubmed: 23524664
Eur J Endocrinol. 2018 Aug 7;179(5):287-297
pubmed: 30087117
Am J Physiol. 1984 Oct;247(4 Pt 2):F632-6
pubmed: 6496691
Ther Drug Monit. 2015 Feb;37(1):58-65
pubmed: 24887633
Methods Mol Biol. 2010;632:99-124
pubmed: 20217574
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
Pharmacogenomics. 2007 Mar;8(3):293-305
pubmed: 17324118
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Biomed Chromatogr. 2012 Nov;26(11):1308-14
pubmed: 22259022
Bioanalysis. 2018 Aug 1;10(15):1229-1248
pubmed: 30033744